The U.S. Interventional Cardiology and Peripheral Market was valued at USD 7.88 billion in 2024, and is projected to reach USD 11.19 billion by 2030, rising at a CAGR of 6.00%. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.
The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.
Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.
This product will be delivered within 2 business days.
The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.
Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.
U.S. Interventional Cardiology And Peripheral Market Report Highlights
- Based on product, the coronary stents segment accounted for the largest revenue share of 41.5% in 2024.
- The segment growth is driven by increasing adoption of Percutaneous Coronary Interventions (PCI), continuous advancements in drug-eluting stent technologies, and favorable reimbursement policies supporting minimally invasive cardiovascular procedures in the U.S.
- Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.
- Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.
- In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope
Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this U.S. Interventional Cardiology and Peripheral market report include:- B. Braun SE
- BD
- Cardinal Health
- Medtronic
- Teleflex Incorporated
- W. L. Gore & Associates Inc.
- Cook
- Boston Scientific Corporation
- AngioDynamics
- Abbott
- OrbusNeich Medical Group Holdings Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 7.88 Billion |
| Forecasted Market Value ( USD | $ 11.19 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
